Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Clinical trial NCT05760612 · RECRUITING

Trial details

NCT number: NCT05760612
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Early-stage Breast Cancer HER2-positive Breast Cancer Adjuvant Treatment After Trastuzumab RCB Classification 1-2 Neratini

Start date: 2023-03-14
Primary completion: 2028-02-16
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.